Showing results (1821-1830 of 1,880) with videos related to

Sort By:
Pageof 188
BMJ Paediatrics Open|March 18, 2026
Growth standards from birth to age 5: a population-specific retrospective longitudinal "WeChildren-Ningbo" study of 500 000 children and comparative analysis with WHO/national referencesLanqiu Lv, Chen Jiang, Yangyang Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 StudySusanna Hegewisch-Becker, Guillermo Mendez, Joseph Chao, et al.
Nature Communications|November 7, 2018
Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumoursZe Rui Wu, Lichong Yan, Yan Ting Liu, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2025
Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvirBu-Fan Yao, Yang Yang, Shan-Sen Xu, et al.
Nature Communications|July 11, 2018
Author Correction: HuR regulates telomerase activity through TERC methylationHao Tang, Hu Wang, Xiaolei Cheng, et al.
Nature|March 29, 2023
Thousands of conductance levels in memristors integrated on CMOSMingyi Rao, Hao Tang, Jiangbin Wu, et al.
Nature Communications|June 9, 2018
HuR regulates telomerase activity through TERC methylationHao Tang, Hu Wang, Xiaolei Cheng, et al.
Medcomm|July 8, 2026
Integrated Genomic, Transcriptomic, and Circulating Biomarkers Predict Benefit to Immune Checkpoint Inhibitor Plus Chemotherapy in Advanced Non-Small Cell Lung CancerLailing Li, Dandan Han, Xiaoliang Zhang, et al.
Virulence|September 23, 2024
Hepatic and extrahepatic metabolic modulation in hbv-related decompensated cirrhosis and acute-on-chronic liver failureZhi-Wei Li, Sheng Tu, Xia Yu, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.
Pageof 188